In terms of later health, loss of imprinting, of IGF2 in particular, is a common characteristic of many cancer types including; breast, lung, colon, liver, ovary but it has been proposed that more subtle epigenetic changes could play a seminal role in the earliest steps in cancer initiation [49]–[51] and variation in imprinting occurs in normal tissue of cancer patients or those at increased risk of the disease [49]. This evidence concerns the gene IGF2 and cancer.